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Abstract
Background: Cohort studies have revealed an increased risk for ventricular fibrillation (VF) and sudden cardiac death
(SCD) in patients with atrial fibrillation (AF). In this study, we hypothesized that single nucleotide polymorphisms (SNP)
previously associated with AF may be associated with the risk of VF caused by first ST-segment elevation myocardial
infarction (STEMI).
Methods: We investigated association of 24 AF-associated SNPs with VF in the prospectively assembled case–control
study among first STEMI-patients of Danish ancestry.
Results: We included 257 cases (STEMI with VF) and 537 controls (STEMI without VF). The median age at index infarction
was 60 years for the cases and 61 years for the controls (p = 0.100). Compared to the control group, the case group was
more likely to be male (86% vs. 75%, p = 0.001), have a history of AF (7% vs. 2%, p = 0.006) or hypercholesterolemia (39%
vs. 31%, p = 0.023), and a family history of sudden death (40% vs. 25%, p < 0.001). All 24 selected SNPs have previously
been associated with AF. None of the 24 SNPs were associated with the risk of VF after adjustment for age and sex under
additive genetic model of inheritance in the logistic regression model.
Conclusion: In this study, we found that the 24 AF-associated SNPs may not be involved in increasing the risk of VF.
Larger VF cohorts and use of new next generation sequencing and epigenetic may in future identify additional AF and VF
risk loci and improve our understanding of genetic pathways behind the two arrhythmias.
Keywords: Ventricular fibrillation, Atrial fibrillation, Myocardial infarction, ST-elevation myocardial infarction, Sudden
cardiac death, Genetics, Single nucleotide polymorphisms
Background
Cohort studies have revealed an increased risk for
ventricular fibrillation (VF) [1–4] and sudden cardiac
death (SCD) [5–7] in patients with atrial fibrillation
(AF). In the Danish GEVAMI (GEnetic causes of Ven-
tricular Arrhythmias in patients with first ST-elevation
Myocardial Infarction) study we have previously demon-
strated a strong association between AF and VF before
primary percutaneous coronary intervention (PPCI) with
an odds ratio (OR) of 2.8 (95% CI: 1.10–7.30) [1]. The
GEVAMI study population includes patients presenting
with first ST-segment elevation myocardial infarction
(STEMI) that do (case) or do not (control) develop VF
prior to primary angioplasty.
Heritable factors and cardiac channelopathies have been
suggested as cause of VF and AF [8, 9]. Genome-wide
association studies (GWAS) in individuals of European,
[10, 11] Asian, [12] and African American [13] descent
have identified several genomic regions with AF.
Especially single nucleotide polymorphisms (SNP) on
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chromosomes 4q25 (PITX2) have strong association with
AF [9, 14], but also with higher risk of SCD [15]. Further-
more, SCN5A and SCN10A which encode the transient
sodium channel (INa) and play a pivotal role in membrane
depolarization during cardiac action potentials have also
been associated with AF, [16, 17] VF [17], and also
Brugada Syndrome [18, 19].
In this study, we hypothesized SNPs that previously
were associated with AF can affect the risk of VF in the
GEVAMI study population and thereby suggest a shared
genetic pathway.
Methods
Study population
The study population and design has been described
previously [1, 20]. In brief, the Danish GEVAMI study is
an ongoing nationwide prospectively collected case-
control study among patients with first STEMI between
the ages of 18 and 80 years [1, 20]. The case group are
STEMI patients who had VF or sustained ventricular
tachycardia (VT; n = 6) with cardiac arrest within the
first 12 h of symptoms of STEMI before PPCI, and the
control group are STEMI patients who did not have VF/
VT. All the patients are collected at all four PPCI
centers in Denmark. Both groups were required to have
cardiac symptoms lasting ≤12 h, acute STEMI on ECG,
which required acute PPCI. Baseline demographics and
previous medical history are collected by research coor-
dinators utilizing pre-designed questionnaires and whole
blood is collected for genetic analysis.
DNA extraction and SNP genotyping
The methods for DNA extraction and also the SNP
genotyping and analysis of this study have been de-
scribed previously in detail [20]. In brief, we used whole
blood and isolated the total genomic DNA using LGC’s
Kleargene™ silica-based DNA extraction technique,
which was performed at LGC Genomics. Isolated DNA
was then analyzed using UV spectrophotometry to esti-
mate both the quality and quantity of the DNA and
normalized.
Based upon the results of previous genetic association
studies, 24 common genetic variants known to be associ-
ate with AF [9–12, 14, 16, 17, 21–27] were selected for
SNP genotyping in both the cases and controls. SNP geno-
typing was performed using KASP™ genotyping assays
from LGC genomics (http://www.lgcgenomics.com). For
each SNP two allele specific forward primers and one re-
verse primer were designed (LGC Genomics, Hoddesdon,
UK) as described in detail previously [20]. All assays were
conducted without any knowledge of case or control sta-
tus. Genotypes for all SNPs passed our quality-control
threshold (call-rate ≥ 94%; Hardy-Weinberg equilibrium
P > 0.05 in control subjects).
Statistical analysis
Medians or proportions of baseline and presenting
characteristics were computed for cases and controls,
and significance of associations were tested using the
Wilcoxon rank-sum test for continuous variables and
the χ2 test or Fisher exact test (where appropriate)
for categorical variables. A two-tailed p value ≤0.05
was considered statistically significant. A logistic re-
gression model were constructed to estimate OR for
the association between each SNP and VF using an
additive model (per copy allele frequency) of inherit-
ance, as described previously [20]. The logistic regres-
sion model was adjusted for age and sex. All analyses
were performed using the Stata software package
version 12.0 (StataCorp).
Results
Clinical characteristics of the cohort
The clinical characteristics of the cohort are described
previously [1, 20]. In total, 257 cases (35 women and
222 men) with VF caused by first STEMI and 537
STEMI controls (131 women and 426 men) who did not
developed VF were included in this prospective assem-
bled study. Table 1 shows the baseline characteristics of
the GEVAMI cohort. The median age of the cases was
60 (interquartile range (IQR); 53–68) years versus 61
(IQR; 52–66) years for the controls. As reported previ-
ously, compared to the controls, cases were more likely
to be male, have atrial fibrillation or hypercholesterol-
emia, and a family history of sudden death [1]. The
statin therapy was higher in the cases compared to the
controls, most likely due to the higher degree of hyper-
cholesterolemia in the cases. Levels of average weekly al-
cohol intake were higher in the cases (6 units/week)
compared to the controls (3 units/week) (P = 0.001).
Regarding other cardiovascular risk factors such as
smoking, diabetes, and hypertension, did cases not differ
significantly from the controls.
Common genetic variants associated with VF
Comprehensive panels of 24 common variants were ge-
notyped in 794 individuals in the GEVAMI population
with Danish descent (Table 2). All the selected SNPs
were reported to be associated with AF. The overall call
rate was ≥95%. Table 2 shows the risk allele frequencies
and the OR for each SNP. The rs6795970 SNP risk allele
A did not exist in our cohort although the average call-
rate was 97.8%. None of the 24 common genetic variants
were associated with the risk of VF in the GEVAMI
population after multivariable adjustment (Table 2).
Discussion
In this study, we investigated the role of 24 common SNPs
previously associated with AF and their associations with
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VF in the setting of first STEMI and found no associations
in the GEVAMI case-control population. To support the
idea behind the hypothesis of this study several cohort
studies including our GEVAMI study [1] have shown an
increased risk for VF in patients with AF [4]. AF at initial
presentation in the context of acute MI has also been as-
sociated with an increased risk of in-hospital VF in the
FAST-MI 2005 registry [3]. Furthermore, a large Dutch
population-based case-control study (the ARREST study)
found similar increases in the risk of out-of-hospital VF
arrest associated with a preceding diagnosis of AF [2]. In
this study, 1397 out-of-hospital VF cases were compared
with 3474 age- and sex-matched controls from the general
population (i.e., without cardiac arrest). AF was associated
with a threefold increased risk of VF (OR = 3.1, 95% CI
2.1–4.5). Lastly, in a Danish cohort AF has been reported
to cause an increased risk of SCD following acute myocar-
dial infarction [6].
Also several genetic studies have supported the idea
behind the hypothesis of this study. The first GWAS
performed on AF identified an association of SNP
rs2200733 on chromosome 4q25 with AF in those of
European and Asian descent [27]. Since this important
finding, several studies have found the same association
Table 1 Baseline characteristics of the cohort
Variables Cases (n = 257) Controls (n = 537) P value
Female sex, No. (%) 35 (14) 131 (25) 0.001
Median Age at index infarction, y (IQR) 60 (53–68) 61 (52–66) 0.100
Cardiovascular risk profile
Body mass index (kg/m2), (IQR) 27.2 (25–29) 26.7 (24–29) 0.400
Smoking (pack year), (IQR) 25 (5–41) 25 (6–42) 0.200
Smoking, No. (%)
Never 38 (16) 108 (20) 0.300
Past 69 (28) 133 (25)
Current 136 (56) 290 (55)
Alcohol per week, (unit*, IQR) 6 (1–15) 3 (0–9) <0.001
Alcohol units per week (categorized), No. (%)
Non-drinkers 46 (19) 143 (27) <0.001
Normal (1–7) 90 (38) 242 (46)
Moderate High (8–14) 41 (17) 70 (13)
High (>15) 60 (26) 73 (14)
Diabetes, No. (%) 30 (12) 47 (9) 0.200
Hypertension, No. (%) 102 (41) 184 (35) 0.070
COPD, No. (%) 12 (5) 30 (6) 0.700
Hypercholesterolemia, No. (%) 97 (39) 165 (31) 0.023
Stroke, No. (%) 18 (7) 26 (5) 0.200
Atrial fibrillation, No. (%) 16 (7) 10 (2) 0.006
Depression, No. (%) 28 (11) 65 (12) 0.700
Epilepsy, No. (%) 4 (2) 5 (1) 0.500
Family History, No. (%)
Sudden death 94 (40%) 128 (25%) <0.001
Myocardial infarction 90 (40%) 195 (38%) 0.600
Stroke 36 (16%) 75 (15%) 0.600
Medication before MI¶, No. (%)
β-blockers 20 (8) 43 (8) 0.900
Statins 55 (22) 65 (12) <0.001
ACE/ARB blockers 50 (21) 90 (17) 0.200
Aspirin 28 (12) 40 (8) 0.060
IQR: interquartile range; unit‡ of alcohol =12 g (1 drink); COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; ACE/ARB: angiotensin-converting-
enzyme inhibitor/ angiotensin II receptor blocker
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in other populations and also with an increased risk for
prolonged PR interval, [28] which has been shown to be
associated with all-cause mortality [29]. In a meta-
analysis involving 716 SCD cases, the rs2200733 variant
in 4q25 was found to be significantly associated with
SCD (relative risk (RR) of 1.28 per minor T allele (95%
CI: 1.11–1.48; P = 7.9 × 10−4) [15]. The latter study
supports a joint genetic pathway between AF and VF or
at least abnormal cardiac function. The rs2200733 has
been associated with expression of PITX2, which is a
transcription factor, and the expression level of PITX2
has been associated with structural changes as well as
expression of ion channel genes such as SCN5A [30].
Furthermore, the SNP rs6795970 which is in high link-
age disequilibrium (r2 = 0.93) with rs6801957 at the
SCN10A locus has previously been associated with
abnormality of cardiac conduction [16, 17, 23]. The SNP
rs6795970 has also been associated with AF in two dif-
ferent studies [23, 24]. Furthermore, Chambers et al.
identified that rs6795970 is associated with prolonged
cardiac conduction (longer P-wave duration, PR interval
and QRS duration) [17]. In contrast, in the same study
[17] the rs6795970 was significantly protective against
risk of VF caused by first STEMI among the 976 partici-
pants in the Arrhythmia Genetics in The NEtherlands
(AGNES) study with an OR of 0.79 (95% CI: 0.66–0.95;
Table 2 Additive genetic model of inheritance (per copy allele frequency) for association of 24 SNPs previously associated with atrial
fibrillation, and in this study investigated for association with ventricular fibrillation before ST-segment elevation myocardial
infarction
Locus SNP RA RAF (Cases/Controls) OR 95% CI P Nearest gene
symbol
1& 1q21 rs6666258 C 0.31/0.33 0.91 0.72–1.15 0.400 KCNN3 [9, 26]
2 1q24 rs3903239 C 0.46/0.49 0.85 0.68–1.07 0.200 PRRX1 [9]
3 3p25 rs4642101 G 0.61/0.62 0.99 0.79–1.25 0.900 CAND2 [22]
4#* 3p21 rs6795970 A 0.00/0.00 – – – SCN10A [17]
5&* 4q25 rs2200733 T 0.08/0.08 0.96 0.65–1.42 0.900 PITX2 [9, 10]
6& 4q25 rs2634073 A 0.14/0.15 0.88 0.65–1.20 0.400 PITX2 [9]
7& 4q25 rs6843082 G 0.16/0.18 0.87 0.66–1.17 0.400 PITX2 [9, 14]
8 4q25 rs1448818 G 0.26/0.24 1.13 0.89–1.43 0.300 PITX2 [21]
9& 4q25 rs10033464 T 0.76/0.94 0.79 0.53–1.17 0.300 PITX2 [21, 27]
10 4q25 rs17570669 T 0.06/0.08 0.74 0.48–1.12 0.200 PITX2 [21]
11 4q25 rs2723288 T 0.29/0.28 1.08 0.86–1.35 0.500 PITX2 [21]
12 4q25 rs4400058 A 0.08/0.09 0.80 0.54–1.18 0.300 PITX2 [21]
13 4q25 rs6838973 T 0.43/0.44 0.95 0.76–1.18 0.700 PITX2 [21]
14 4q25 rs3853445 C 0.26/0.25 0.99 0.78–1.27 0.900 PITX2 [21]
15 5q31 rs2040862 T 0.18/0.16 1.15 0.87–1.53 0.300 PITX2 [21]
16 6q22 rs13216675 T 0.68/0.69 0.95 0.75–1.18 0.600 GJA1 [22]
17 7q31 rs3807989 G 0.41/0.42 1.00 0.81–1.25 0.900 CAV1 [9]
18 9q22 rs10821415 A 0.39/0.39 0.97 0.78–1.20 0.800 C9ORF3 [9]
19 10q22 rs10824026 G 0.13/0.15 0.85 0.62–1.16 0.300 MYOZ1 [9]
20 10q24 rs12415501 T 0.15/0.16 0.92 0.68–1.23 0.600 NEURL [22]
21 12q24 rs10507248 T 0.75/0.74 1.05 0.82–1.33 0.700 TBX5 [22]
22 14q23 rs1152591 T 0.51/0.48 1.11 0.89–1.38 0.300 SYNE2 [9]
23 15q24 rs7164883 G 0.17/0.13 1.28 0.96–1.70 0.090 HCN4 [9]
24 16q22 rs2106261 A 0.18/0.17 1.09 0.83–1.44 0.500 ZFHX3 [9, 36]
SNP: single-nucleotide polymorphism; RA: Risk allele; RAF: Risk allele frequency in cases over controls in our cohort; OR: odds ratio; CI: confidence interval; P value
for the additive genetic model of inheritance (per copy allele frequency)
#: No risk allele (A) exists in the GEVAMI cohort. Logistic regression models under an additive model of inheritance adjusted for age and sex. Number of
cases = 257; number of controls = 537
&: The SNP rs6666258 is in linkage disequilibrium (r2 = 1.00) with rs13376333
&: The SNP 2200733 is in linkage disequilibrium (r2 = 1.00) with rs6817105 and rs17042171
&: The rs2634073 is in linkage disequilibrium (r2 = 0.80) with rs6843082
&: The rs10033464 is in linkage disequilibrium (r2 = 1.00) with rs4032974
*: The SNP rs6795970 and 2,200,733 are both associated with SCD [20]
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p = 0.01). In the GEVAMI cohort we were not able to
show an association between the SNP rs6795970 and
VF. Obviously, since the A risk allele did not exist in the
current GEVAMI population. This could be due to the
selected STEMI population, and according to our
knowledge the frequency of this SNP is not reported in
a general Danish population. However, as a proxy for the
SNP rs6795970, we previously published another SNP
(rs10428132) which is also located near the SCN10A
gene at chromosome 3, and which is in highly linkage
with SNP rs6795970 (r2 = 0.966) and found no associ-
ation with VF [20]. However, the mechanisms linking
genetic variants in SCN10A with cardiac conduction re-
mains to be determined. As mentioned earlier several
studies have found rare and comment variants associ-
ated with AF. However the present AF-data only ac-
count for a very limited percentage of the heritability of
AF and this is also the case for SCD and VF caused by
STEMI. Therefore, identification of additional AF and
VF loci by new technologies such as next generation se-
quencing may improve our knowledge of heritability of
AF and VF and thereby understanding of if a shared
genetic mechanism exists between the two arrhythmias.
There is also evidence for the proarrhythmic feature of
AF, which by itself can induce VF without genetic
involvment [31]. One study suggested that rapid
ventricular rate during AF will reduce the ventricular re-
fractoriness and induce ventricular tachyarrhythmia [32].
Moreover, the irregular rhythm of AF may cause VF
through abrupt short-to-long changes in the cycle
length, [33] and in AF patients with an implantable car-
dioverter defibrillator have more frequently and signifi-
cantly induced VT/VF [34]. Lastly, AF by hemodynamic
changes, can decrease parasympathetic tone and
increase sympathetic tone making emerging of VF more
likely [35].
The strength of the GEVAMI study is the prospective
design and the use of a well-defined phenotype (VF). It is
possible that some of these SNPs would have reached sig-
nificance in a larger sample. In current study, the absolute
number of patients with AF was low. A total of 16 (7%)
cases and 10 (2%) controls were known with previous AF.
Given our relatively low sample size, we acknowledge that
this study may has been underpowered to detect associa-
tions. Most AF SNPs are high-frequency variants with
small incremental effects on risk and therefore may limit
the ability of this study to find association of AF-variants
with small effect size. It is also important to mention that
collecting cases is very time consuming and limited due to
relatively low incidence of VF and difficulties to enroll and
collect blood samples in STEMI-patients with VF and car-
diac arrest. This is mostly due to that patients who died
outside of the hospital or died in-hospital prior to enroll-
ment cannot be included. The association of AF and VF in
the cohort studies may be due to that AF patients have
more comorbidity and therefore develop VF during acute
ischemia. We only included patients with VF within 12 h
before PPCI, therefore our data only represent patients
with VF within this time interval since patients with late
VF (VF after 12 h, or VF during PPCI) were excluded. Fi-
nally, our results in this population with white, European
ancestry may not be generalizable to other populations.
Conclusion
In this study we found that the 24AF-associated SNPs
may not be involved in increasing the risk for VF. The
complexity and interconnections between the two ar-
rhythmias needs to be investigated in larger aspects and
not only based on SNPs. Larger VF cohorts and use of
new next generation sequencing and epigenetic may in
future identify additional AF and VF risk loci and im-
prove our understanding of genetic pathways behind the
two arrhythmias.
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